Age and sex-standardised incidence rates and 95% CIs in b/tsDMARD switchers, first b/tsDMARD users and csDMARD users
| b/tsDMARD switchers | First b/tsDMARD users | csDMARD users | |
| VTE | 0.86 (0.70 to 1.03) | 0.60 (0.52 to 0.68) | 0.58 (0.51 to 0.65) |
| DVT | 0.57 (0.44 to 0.70) | 0.45 (0.38 to 0.52) | 0.42 (0.36 to 0.48) |
| PE | 0.48 (0.34 to 0.61) | 0.27 (0.21 to 0.32) | 0.26 (0.22 to 0.31) |
Age and sex-standardised incidence rate was calculated by applying age and sex-specific incidence rates (ie, 18–44, 45–64, 65–74 and 75+ for men and women) to population age and sex distribution from US Census 2010 in a direct method,47 with 95% CIs estimated using normal approximation.48
b/tsDMARD, biologic or targeted synthetic disease-modifying antirheumatic drug; csDMARD, conventional synthetic DMARD; DVT, deep vein thrombosis; PE, pulmonary embolism; VTE, venous thromboembolism.